598 5. 6. 7. Hospital Pharmacy 52(9) Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099. doi:10.1056/NEJMoa1206797. Lincoff AM, Nicholis SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933-1942. doi:10.1056/ NEJMoa1609581. The HPS3/TIMI55 -REVEAL Collaborative Group.Effects of anacetrapib in patients with atherosclerotic vascular disease. N 8. 9. Engl J Med. 2017 Aug 29; [e-pub]. (http://dx.doi.org/10.1056/ NEJMoa1706444). Ference BA et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 2017 Aug 28; [e-pub]. (http://dx.doi. org/10.1001/jama.2017.11467). Prescribe Right Pharmaceutical Pipeline Tracker, 2017, http:// www.prescriberight.com/pharmaceutical-pipeline-tracker. html Accessed July 28, 2017.http://dx.doi.org/10.1056/NEJMoa1706444 http://dx.doi.org/10.1056/NEJMoa1706444 http://dx.doi.org/10.1001/jama.2017.11467 http://dx.doi.org/10.1001/jama.2017.11467 http://www.prescriberight.com/pharmaceutical-pipeline-tracker.html http://www.prescriberight.com/pharmaceutical-pipeline-tracker.html http://www.prescriberight.com/pharmaceutical-pipeline-tracker.html